Monday, April 15, 2024
AAN Vision
To be indispensable to our members
AAN Mission
To enhance member career fullfillment and promote brain health for all
American Academy of Neurology
201 Chicago Avenue
Minneapolis, MN 55415 USA
Phone: (800) 879-1960 (Toll Free) or (612) 928-6000 (International)
Fax: (612) 454-2744
Email: memberservices@aan.com
Website: AAN.com
AAN Chief Executive Officer:
Mary E. Post, MBA, CAE
Managing Editor:
Angela M. Babb, MS, CAE, APR
Editor: Sarah Parsons
Writers: Ryan Knoke, Val Lick
Designers: Andrew Imholte, Jim Hopwood
Photography: Will Evans
Annual Meeting Daily is published by the American Academy of Neurology.
The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world. “American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.
Late Start Monday!
Rest up after the Annual Meeting Party and use the morning to watch past sessions, catch up on work, or enjoy some downtime before the start of the day's programming.
*Start and end times may vary. Check with each hosting company for further information.
The issues most critical to practicing neurologists will be explored by leading researchers as they discuss abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments already affecting the practice of neurology during this morning’s Contemporary Clinical Issues Plenary. Set to take place between 9:15 a.m. and 11:00 a.m. in the Bellco Theatre, the session will be moderated by Elizabeth Ann Felton, MD, PhD.
Session Moderator:
Elizabeth Ann Felton, MD, PhD, Member, Science Committee
Topics and presenters include:
Cutaneous Phosphorylated AlphaSynuclein Deposition in Dementia with Lewy Bodies and Mild Cognitive Impairment
Presenter: Christopher H. Gibbons, MD, FAAN, Beth Israel Deaconess Medical Center, Boston, MA
Discussant: Sonja Waltraud Scholz, MD, FAAN, National Institutes of Health, Bethesda, MD
Head over to the Research Hub in the Exhibit Hall B–E after the session to engage with and ask questions of plenary moderators and presenters during the live, 30-minute “Fireside Chat.”
The Role of Neurocritical Care Specialists in Brain Death Testing
Presenter: Neil Dhruva, Emory University, Atlanta, GA
Discussant: Ariane Lewis, MD, FAAN, New York University Langone Health, New York, NY
The Association Between Neighborhood Disadvantage and Subjective Cognitive Functioning Among Black Women
Presenter: Tanisha Hill-Jarrett, PhD, University of California San Francisco, San Francisco, CA
Discussant: Raina Croff, PhD, Oregon Health and Science University, Portland, OR
What was your greatest takeaway from the Contemporary Clinical Issues Plenary? Join the conversation at #AANAM
Multi-institutional Study of Neurologic Outcomes in People with Multiple Sclerosis Who Are Treated with Immune Checkpoint Inhibitors for Oncologic Indications
Presenter: Prashanth Rajarajan, MD, PhD, Brigham and Women’s Hospital, Boston, MA
Discussant:
Kristin Marissa Galetta, MD, Stanford University, Palo Alto, CA
Prevalence and Co-morbidities of GI Disorders in Migraine in Large Tertiary Medical Center
Presenter: Natalia Murinova, MD, FAAN, University of Washington, Seattle, WA
Discussant: Bridget Rita Mueller, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY
If you’re a medical student, resident, or fellow looking to give a boost to your journey into neurology, then you won’t want to miss tonight’s Trainee and Faculty Networking Reception taking place from 6:00 p.m. to 8:00 p.m. at the Hyatt Regency Denver Centennial A-E. It’s here where you’ll gain new perspectives and insights and make lasting connections that could help further your career development in academic neurology, research, or practice. Meet one-on-one with both peers and seasoned program and clerkship directors to ask questions and learn about traversing this exciting field. Program and clerkship directors are also encouraged to attend to connect with peers and discuss their programs and education techniques. Faculty representatives from various institutions will be on hand to share information about their programs and discuss the prospects of clerkships, residencies, fellowships, and other neurology career opportunities.
The Trainee and Faculty Networking Reception is sponsored by:
Who better than your fellow Denver-based AAN member colleagues to offer up an insider’s take on the must-knows to make your week in the Mile High City even more memorable.
“If one has the time and transportation, a day trip to the mountains is a must. Depending on the snow, Cooper Mountain, Breckenridge, Keystone, and Arapahoe Basin should be open for downhill skiing.”
–Katie Coerver, MD, PhD, FAAN
“Golden is a Western-feeling town a local train or 20-minute cab ride away. Boulder is about 40 minutes away and is scenic. It’s also great to walk up and down the Pearl Street shops.”
–Russell Bartt, MD, FAAN“If you can spend some extra time in Colorado, the Rocky Mountains are a must see! In April, there is still spring skiing at many of the resorts. Another popular place with great views that is a bit closer to the city is the Red Rocks Park and Amphitheatre.”
–Amanda L. Piquet, MD, FAAN
“The ultimate ‘must-see’ attraction are the mountains—you have different spots from the city—my favorite spot is in front of the Denver Museum of Nature and Science (City Park), but there are other spots where people can just be amazed by our beautiful landscape.”
–Karen Dianne Orjuela, MD, FAAN
Join our expert panel as they discuss current topics regarding the use of VYVGART for intravenous infusion and VYVGART HYTRULO for subcutaneous injection in anti-acetylcholine receptor antibody (AChR-Ab) positive generalized myasthenia gravis, including pathophysiology, long-term clinical data, and observational real-world data.
Neelam Goyal, MD
Clinical Associate Professor, Division of Neuromuscular Medicine, Stanford University
Kelly G. Gwathmey, MD
Associate Professor and Director, VCU ALS Clinic and Division of Neuromuscular Chief, Virginia Commonwealth University
Professor of Neurology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo Monday,
Nicholas J. Silvestri, MD, FAAN
INDICATION
VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART® HYTRULO (efgartigimod alfa and hyaluronidaseqvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VYVGART and VYVGART HYTRULO are contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART or VYVGART HYTRULO, respectively. VYVGART HYTRULO is also contraindicated in patients with serious hypersensitivity to hyaluronidase. Reactions have included anaphylaxis and hypotension leading to syncope.
WARNINGS AND PRECAUTIONS
Infection
VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infection (33% of efgartigimod alfa-fcabtreated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay the administration of VYVGART or VYVGART HYTRULO in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding treatment with VYVGART or VYVGART HYTRULO until the infection has resolved.
Immunization
Immunization with vaccines during treatment with VYVGART or VYVGART HYTRULO has not been studied; the safety with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because VYVGART and VYVGART HYTRULO cause a reduction in immunoglobulin G (IgG) levels, vaccination with live-attenuated or live vaccines is not recommended during treatment with VYVGART or VYVGART HYTRULO. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART or VYVGART HYTRULO.
Hypersensitivity Reactions
In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART or VYVGART HYTRULO. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Healthcare professionals should monitor patients during and for 1 hour after VYVGART administration, or for at least 30 minutes after VYVGART HYTRULO
administration, for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.
Infusion-Related Reactions
Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusionrelated reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. If a severe infusion-related reaction occurs with VYVGART HYTRULO, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART or VYVGART HYTRULO following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.
ADVERSE REACTIONS
In Study 1, the most common (≥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the most common (≥10%) adverse reactions in VYVGART HYTRULOtreated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULOtreated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 2 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.
USE IN SPECIFIC POPULATIONS
Pregnancy
As VYVGART and VYVGART HYTRULO are expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risks and benefits should be considered prior to administering live or live attenuated vaccines to infants exposed to VYVGART or VYVGART HYTRULO in utero.
Lactation
There is no information regarding the presence of efgartigimod alfa-fcab from administration of VYVGART, or efgartigimod alfa or hyaluronidase from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART or VYVGART HYTRULO, and any potential adverse effects on the breastfed infant from VYVGART or VYVGART HYTRULO or from the underlying maternal condition.
Please see the full Prescribing Information for VYVGART and the full Prescribing Information for VYVGART HYTRULO.
You may report side effects to the US Food and Drug Administration by visiting http://www.fda.gov/medwatch or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).
The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.
$75K Members
$50K Members
$25K Members
Alnylam Pharmaceuticals, Inc.
Amneal Specialty, a division of Amneal Pharmaceuticals LLC
Biogen
Biohaven
Cerevel Therapeutics
Harmony Biosciences
Illumina
Ionis Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Neuroscience
Jazz Pharmaceuticals
PTC Therapeutics
Xenon Pharmaceuticals
$10K Members
Bayer
C2N Diagnostics
Octapharma
RISE Healthcare Group
Roche Sandoz
Current as of March 21, 2024
Treating AD is about more than just removing plaque.
Get the whole story at Eisai Booth 1325.
Today’s Neuroscience in the Clinic session from 3:30 p.m. to 5:30 p.m. in rooms 108, 110, and 112 will focus on major physiological changes that occur during the menopausal transition and postmenopausal decades—including those that arise in nerves and glia, as well as in other systems such as cardiovascular, immune, and musculoskeletal—that can influence neurologic functions. Join Directors Rashmi B. Halker Singh, MD, FAAN, and Riley Bove, MD, FAAN; expert faculty Aleksandra Pikula, MD; and abstract presenters Gaia Patane, MD, and Victoria Michelle Rice, DO, as they explain the evidence of these changes and their impact on perimenopausal and postmenopausal brain health. The session will conclude with a panel discussion along with an opportunity for questions. Attendees may claim two CME credits.
The AAN Conferences mobile app makes finding your way to sessions easier than ever. For help navigating through the convention center, tap the listed location in the session you want to attend.
Far away from your next session? Use the livestream feature to view it on-the-go. Tap “Happening Now” on the main menu to find a session and select the “play” icon. Livestreams are available for most sessions.
Need mobile app support? Visit the Information Booth by the Big Blue Bear.
The AAN continually works to improve the Annual Meeting experience—and we’re counting on you to provide your honest feedback about the overall meeting and individual sessions! Not only will your feedback be used by the various planning committees when they are evaluating this year’s meeting and planning for the next one, but it’s also your opportunity to claim your much-needed CME.
Evaluations can be accessed on the mobile app, AAN.com/AMCME, the online platform, or by scanning the QR code below. The deadline to complete evaluations is May 1, 2024 (or March 1, 2025, if you added Annual Meeting On Demand to your registration). Thank you!
Understanding Open Access, Free Access, Predatory Journals, and Funders’ Mandates
2:00 p.m.–2:30 p.m.
Exhibit Hall B-E (Research Hub)
What do you need to know about open and free access, predatory journals, and funders' mandates? Bring your questions for this discussion on current scenarios and the possible future of these topics.
4:15 p.m.–5:00 p.m.
Grand Concourse (Publications Booth)
In honor of the 20th anniversary of the Resident & Fellow Section (RFS), the RFS will host an alumni panel composed of neurologists from a variety of careers who will share career advice for trainees, how involvement in the RFS helped launch their careers, and other lessons learned. They will also highlight opportunities for career growth and development for trainees beyond the RFS.
Neurology Today® At the Meetings features curated news from major neurology meetings—including the Annual Meeting. Check your email for highlights and analysis of the top-ranked abstracts.
The only cutaneous test to help diagnose Parkinson’s disease and related disorders
A new diagnostic standard is emerging with the Syn-One Test, offering increased clarity and confidence through reliable detection and visualization of phosphorylated alpha-synuclein in cutaneous nerves.
Learn more about the Syn-One Test cndlifesciences.com
>95% sensitivity & specificity*
Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. Published online March 20, 2024. doi:10.1001/jama.2024.0792
Utilizes a simple in-office skin biopsy procedure
Ordered by clinicians for more than 20,000 patients
For easy access to meeting links, visit AAN.com/QuickLinks.
Slides are available online only at AAN.com/Materials or through the AAN Conferences mobile app. You can access program materials through March 1, 2025. (Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)
Add Annual Meeting On Demand to your registration now to save up to 55% and extend your access to session recordings through March 1, 2025. Check the back of your badge to see if you already have Annual Meeting On Demand. If not, head to the Online Learning booth in the Grand Concourse or email aanamsupport@cmrus.com by May 6, 2024, to add it to your registration.
Stop by the AANTV Studio in Lobby D to witness live interviews being recorded for later broadcast on the online platform, TV monitors around the convention center, and on AAN.com and YouTube. Visit AAN.com/AANTV to watch today's segment!
Attendee lunch is included in your registration fee and served from 11:30 a.m. to 1:00 p.m. in Exhibit Hall B-E, near the posters. Lunches are served in compostable boxes to help the AAN’s sustainability efforts.
Join us for the Exhibit Hall Networking Crawl from 4:00 p.m. to 6:00 p.m. in Exhibit Hall B-E for a walking food tour to various delicious stations allowing you to discover new cuisines and new contacts!
Complete your evaluations to get your CME credits by May 1, 2024 (or March 1, 2025, with Annual Meeting On Demand) by using the AAN Conferences mobile app or by visiting AAN.com/AMCME. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker
The AAN will transition to a new customer relationship management system May 2-14, 2024. CME earned during this period won’t appear immediately in NeuroTracker or the member’s AAN transcript. Evaluations can still be completed during this transition. CME credits earned during this period should appear by mid- to late-May.
Conference attendees have access to content on AAN Rewind through May 6, 2024. Visit AAN.com/AMOnline and use your 6-digit ID and password to log in. It may take up to 48 hours after course completion for content to become available on AAN Rewind.
Sustainability efforts for the 2024 Annual Meeting include using digital communications, prioritizing environmentally friendly materials, and providing water bottle refilling stations. Remember to recycle this issue of Annual Meeting Daily! To learn more, visit AAN.com/AMFAQ.
View all conference guidelines at AAN.com/ConfGuidelines
.
Step outside the traditional classroom and into the world of out-of-the-box learning with eight hub areas. Each hub offers unique educational and networking opportunities and creative programs that leave participants with take-home skills and resources for their patients, practices, and careers.
Here are today’s highlights:
Associate Professors as Mentors and Mentees:
The Sandwich Rank
2:00 p.m.–2:45 p.m.
Associate professors must learn the art of mentoring both up and down the ladder of success. Brian D. Berman, MD, MS, FAAN, S. Elizabeth Zauber, MD, FAAN, and Samantha K. Holden, MD, MS, FAAN, will provide tips on how to be a good mentor, keys to mentoring up, and how to surround yourself with good mentees and mentors.
3:30 p.m.–4:15 p.m.
Health services research (HSR) in neurology is evolving as an important field of study that assesses the quality, safety, efficacy, efficiency, equity, and patient centeredness of health care delivery. The AAN has invested heavily in developing this field through the establishment of the Health Services Research Subcommittee and the funding of studies that assess the value of neurology and the effect of the continuous evolution of health care on the practicing neurologists and neurology patients. Hear from Gregory J. Esper, MD, MBA, FAAN, Brian Callaghan, MD, MS, FAAN, and Michelle H. Leppert, MD, about the Academy’s approach to HSR, prior research that has influenced the field, and upcoming studies that are planned.
The Neurology of Optical Illusions and Other Misperceptions
1:45 p.m.–2:30 p.m.
Tilton
Join this talk by Ann H. Tilton, MD, FAAN, to better understand how our brain brings us illusions and, too often, misperceptions.
3:00 p.m.–4:00 p.m.
Kiran Thakur, MD, FAAN, Katherine B. Peters, MD, PhD, FAAN, and Corey Saperia, MD, will discuss what is happening to the brain of an individual under hypnosis. How does one use hypnosis in medicine and neurology? During this not-to-miss session, learn from experts and see a demonstration by a local hypnotist, Bruce Black, who will hypnotize audience volunteers.
You can find plenty of fun ways to learn at the Annual Meeting!
Ismail I. Ibrahim, MD, Omar A. Danoun, MD, and Ahmed Abd Elazim, MD, competed Sunday in Neuro-Jeopardy (HeadTalks).
Exhibit Hall B-E
Brainstorm—A Competition for the Innovator in All of Us
4:15 p.m.–5:30 p.m.
Which team will prevail in the newly revamped Brainstorm Competition, where groups work together to present on and answer a question given to them on the spot?
Daily Paint and Wine Sessions
12:00 p.m. and 2:00 p.m. in the Exhibit Hall
Don’t miss out—these popular sessions fill up fast!
Leadership University
Mile High 4AB
What I Wished I Had Known Prior to Finishing Residence or Fellowship
11:30 a.m.–12:30 p.m.
Hope O’Brien, MD, FAAN, MBA, Stephanie Vertrees, MD, and James W. M. Owens, Jr., MD, PhD, will help attendees identify what questions and information they need to know prior to going into the academic versus private practice career track, non-clinical options within the field of neurology, and additional skills needed to maintain fulfillment in a career in neurology.
Women in Leadership
2:30 p.m.–3:30 p.m.
This session is for professional women striving to increase their leadership and sphere of influence in their career. Professional development expert Caroline Desmarais will discuss gender-specific challenges and solutions and how to be an impactful female leader. Attendees will learn about building confidence and motivation, increasing their well-being, finding balance in their lives, and leading with purpose.
Lobby F
2024: A Coding Odyssey
2:30 p.m.–3:00 p.m.
Coding experts Sayona John, MD, FAAN, Brian T. Cabaniss, MD, and Gabriela De Bruin, MD, host an interactive, Jeopardy-style session to test attendees’ knowledge on E/M coding and other non-face-to-face service codes. You will have the opportunity to ask questions on each topic or on any billing issues you have encountered in your practice.
Valued Utilization of the APP on the Neurology Care Team
3:30 p.m.–4:30 p.m.
Each member of the care team should be utilized in a meaningful way to improve patient access to care, clinical outcomes, and professional satisfaction. Joan Miravite, DNP, RN, FNP-BC, FAAN, Lucretia Long, CNP, and Shannon Anderson, PA, will discuss how to establish effective teamwork, recognize the inherent value of the team model, and commit to building effective relationships.
Exhibit Hall D Lobby
Finding a Mentor for Your Research Career
3:00 p.m.–3:30 p.m.
Learn effective strategies and discuss ways to find the mentor who supports and challenges you toward success in your research career.
Leveraging REDCap and Clinical Data Collection Systems
3:30 p.m.–4:00 p.m.
Join Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN, to unravel the inner workings of REDCap and other clinical data collection systems. You’ll have the opportunity to share your experiences, pose questions, and engage with fellow researchers dedicated to advancing the neurology field through data management solutions.
Lobby D
Student Interest Group in Neurology (SIGN) Meeting
11:15 a.m.–12:30 p.m.
This meeting and networking session for SIGN students and advisors will aid SIGN leaders and faculty advisors in collaborating with each other on events and provide resources on starting new SIGN chapters.
ABPN Certification and the RITE
3:00 p.m.–5:00 p.m.
Explore lifelong learning and the role played by the American Board of Psychiatry and Neurology (ABPN) certification, as well as the RITE® (Residency In-service Training Exam). This will be a panel discussion with plenty of time for questions and answers.
Exhibit Hall D Lobby
Fashion in the Workplace: How Being Your Authentic Self Can Promote Wellness
3:00 p.m.–3:45 p.m.
Hope O’Brien, MD, FAAN, MBA, Rana R. Said, MD, FAAN, and Belinda A. Savage-Edwards, MD, FAAN, will give tips on choosing your personal professional style.
Together with our customers and global network of research sites, we bring neurological therapies to patients who need them most.
Learn how we can transform clinical development together at parexel.com
If you’re looking for the most timely, significant, and innovative research in neurology, then look no further than the abstracts set to be showcased in today’s Emerging Science program from 11:15 a.m. to 12:45 p.m. in Bluebird 1A. An additional Emerging Science session will be held Tuesday, April 16, from 5:30 p.m. to 7:00 p.m. in Bluebird 1A.
Abstracts selected for Emerging Science presentations include key aspects of research conducted after the October 2023 abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. These previously unpublished abstracts contain timely, significant, and innovative content.
11:15 a.m.–11:21 a.m.
Positive Disease Modifying Effects of Oral ALZ-801 on Plasma Biomarkers, Volumetric MRI, and Cognition at 104 Weeks: Results of a Phase 2 Study in APOE4 Carriers with Early Alzheimer’s Disease
Presenter: James P. Kesslak, PhD
11:21 a.m.–11:27 a.m.
Primary and Secondary Results of LUMINESCE, a Phase 3 Study of Interleukin-6 Signaling Inhibition by Satralizumab in Generalized Myasthenia Gravis
Presenter: Ali A. Habib, MD
11:27 a.m.–11:33 a.m.
Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Patients with Developmental and Epileptic Encephalopathies (DEEs): Results of the Phase 1b/2a PACIFIC Study
Presenter: Randall Kaye, MD
11:33 a.m.–11:39 a.m.
Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping
Presenter: Perry Shieh, MD, PhD, FAAN
11:39 a.m.–11:45 a.m.
Limbic Posterior, Peri-Central, and Paralimbic Cortical Cholinergic Losses Predict Cognitive Changes in Parkinson Disease: A Two-year Longitudinal [18F]-FEOBV PET Study
Presenter: Taylor Brown
11:45 a.m.–11:51 a.m.
Long-term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Interim Analysis of a Phase 3, Multicenter, Open-label, 156-week Long-term Safety Extension Study
Presenter: Sait Ashina, MD
11:51 a.m.–11:57 a.m.
Safety, Pulmonary Function, and Motor Function in Ambulatory and Nonambulatory Participants with Duchenne Muscular Dystrophy Treated with Viltolarsen: Results from the Galactic53 Clinical Trial
Presenter: Michelle Previtera, PhD
11:57 a.m.–12:03 p.m.
Results of the ARCADIA-CSI Cognition Study
Presenter: Ronald M. Lazar, PhD, FAHA, FAAN
12:03 p.m.–12:09 p.m.
Lecanemab for the Treatment of Early Alzheimer’s Disease: The Extension of Efficacy Results from Clarity AD
Join several experts in neurology and public health today for the Health Care Equity Symposium. This thought-provoking event, which will take place from 1:00 p.m. to 4:00 p.m. in Bluebird 1C, will begin with a keynote address from Bernadette Boden-Albala, DrPH, on the current state of health equity across neurologic diseases.
Boden-Albala will describe multi-level strategies for equitable brain health; review current research, practice, and policy strategies that reduce the burden of neurologic disease and target social determinants of health; and highlight the importance of preventative care.
The symposium, which is directed by Jeffrey C. McClean, II, MD, FAAN, also features Raina Croff, PhD, Mathula Thangarajh, MD, PhD, FAAN, and Galit Levi Dunietz, PhD.
Make your way to the Annual Meeting Exhibit Hall this evening between 4:00 p.m. and 6:00 p.m. for the fun—and delicious— networking crawl. Take a walking food tour to explore stations serving up a tasty array of cuisines and beverages while socializing with exhibitors and other attendees—including Sarah Bellum™ learning about the latest advancements in patient care and products that add efficiencies to your practice, and making lasting connections. Thanks to our Networking Crawl sponsors:
• Grifols Shared Services North America
• Janssen Neuroscience
• UCB, Inc.
Boden-Albala
Stop by booth 740 in Exhibit Hall B-E to learn about neurologic subspecialty physician certification and accredited fellowship program opportunities through the United Council for Neurologic Subspecialties (UCNS). As neurology's recognized certifying and accrediting body for emerging subspecialties, the UCNS currently provides accreditation and/or certification for the neurologic subspecialties of Autonomic Disorders, Behavioral Neurology & Neuropsychiatry, Clinical Neuromuscular Pathology, Geriatric Neurology, Headache Medicine, Interventional Neurology, Neonatal Neurocritical Care, Neuroimaging, Neurocritical Care, and Neurooncology. The UCNS has over 242 accredited fellowship programs and over 3,000 certified physicians in the United States and Canada. Staff will be on hand in the booth to share information and answer questions about UCNS certification, continuous certification requirements, fellowship program accreditation requirements, and accredited subspecialty fellowship opportunities.
The UCNS will also have representatives available at the Trainee and Faculty Reception on Monday from 6:00 p.m. to 8:00 p.m. at the Hyatt Regency Denver to answer questions and provide information for trainees about UCNS-accredited subspecialty fellowship programs.
New data highlight the importance of looking for LEMS (Lambert-Eaton myasthenic syndrome) in patients with an MG diagnosis who have autonomic dysfunction— especially those with associated SCLC.1
LEMS=Lambert-Eaton myasthenic syndrome; MG=myasthenia gravis; SCLC=small cell lung cancer.
Reference: 1. Vernino S, Morrell D, Shechter G, Grebla R, Rosenfeld J. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) may be missed among patients with myasthenia gravis and autonomic dysfunction: results from a US database analysis. Abstract presented at: American Academy of Neurology (AAN) annual meeting. April 13-18, 2024; Denver, CO. ©
For neurology professionals at mid-career (or later), job interviews can be a mixed bag. On the one hand, they’re an opportunity, as always, to present your strengths and learn where you’d fit in an organization, whether that’s a hospital, practice group, or somewhere in private industry. The conversation also provides a chance to ask deeper questions about a department’s plans and to position yourself as someone who can help solve anticipated problems. That’s all good, but what about the other side of interviewing at mid-career? Consider this short list of possible pitfalls for experienced job candidates:
• Perceptions of age issues that can cloud the interviewer’s judgment
• Candidate difficulty compressing decades of experience into sound bites
• “Starting over” syndrome, as in: can this candidate learn new systems?
• Questions of “fit” and teamwork for candidates with strong personalities
Complicating these issues are factors related to career cycles: What if this candidate plans to retire in a few years? For the most part, candidates at mid-career will have resolved these concerns for themselves long before they land in an interview. The trick is finding ways to convey the answers to questions the interviewer may not directly ask. Indeed, some interviewers give such a wide berth to issues pertaining to age (to
avoid perceptions of discrimination), entire topics go untouched in the conversation. That’s not necessarily a good thing, particularly if the candidate loses an opportunity to set someone’s mind at ease, or to highlight an age-related advantage. Luckily, there are no restrictions on the candidates themselves regarding what information can be volunteered. The key is to be strategic and intentional as you guide interviewers to a better understanding of your strengths and away from perceived weaknesses for the position. Follow the tips below to give yourself a head start on developing a strategy for your next round of interviews.
1. Develop a key message platform. Do you know which of your many strengths will be most important for the next position? The answer will vary according to setting and the tasks they need you to perform, so this analysis is best done before every interview. The goal is to boil your extensive experience down to three or four talking points that best illustrate your key strengths.
2. Create an interview document to support your key messages.
If you’re scheduled for an interview, your CV or resume has likely been viewed already. Now that you know you’ll be having the conversation, you can create a short, one- or two-page document presenting just the highlights of your experience as
related to the current opening. If you use your key messages as a guide, you’ll be able to create a page that subtly directs the interviewer’s questions while ensuring you’re able to discuss your best points.
3. Practice answers to the most anticipated questions.
As an experienced worker, you’ll do better if you present clear but short answers that connect directly to the work being discussed. This will help you avoid the common pitfall of “in-my-day” answers that give too much detail or inadvertently define you as being over-qualified.
4. Visualize.
The longer you’ve worked in one place or capacity, the more acute the danger that you’ll answer questions from a single frame of reference— which is one of the ways experienced workers signal that they’re stuck in a rut. To remedy this problem, visualize everything you can about the position, from the organization or department to the patients or the workload, to, most especially, the person or people who will make the hiring decision. What would be their concerns? What are their pain points? Having done this exercise, it will be easier to craft messages focused on how you can help them reach their goals.
5. Update your appearance.
It’s fine—good, in fact— to look your age. You just don’t want to look like you belong to a different era. If this isn’t your strong suit, employ the assistance of an image professional to provide guidance on your choices of hairstyle, eyewear, and clothing so you can project a professional, dignified, and up-to-date image.
If you follow each of these tips, you’re likely to find that you’re better prepared for the interview than most of the people you’ll encounter on the other side of the desk. Take comfort in that knowledge, but don’t take it for granted. Job interviews are less frequently won by the person who knows the most than by the person who is best liked or whose potential to help the organization seems greatest. For seasoned professionals, that means a message of
“I know more than the other (younger) candidates” will not be as effective as “I can use my experience to help your department.” Which brings us to the last and possibly most important tip of all for mid-career neurology professionals: Emphasize how your strengths will help the organization reach its goals. To set the right tone, you’ll want to be specific but not overly “instructive,” as demonstrated in the following answers to the same interview question.
Question: We see you’ve had experience developing staffing solutions in your last practice. Tell us more.
Answer 1: Basically, the best way to handle a situation like that is to…(detail here). Once I brought these solutions to the practice management team, I was able to make the point that…(detail here). We implemented my plan by following these steps (list steps) and the results were (name results). So yes, I’m proud of that and I know I could make a similar impact for you.
Critique: Although this might seem like a good answer because it’s rich in detail, the tone is all wrong. The listener is being lectured and overwhelmed but not actually engaged. Worse, if there’s an age difference between the interviewer and the candidate, this kind of answer will play into stereotypes about the older worker dominating work teams.
Answer 2: As we were discussing earlier, I was part of a threephysician practice that had grown very quickly— similar to the situation you’ve been describing here. The long wait times for appointments were affecting the patients and it wasn’t a sustainable model, given the changes we were absorbing at the same time from the insurance payment processes. I can give you more detail on the actual steps we took but the core of the solution was for me to gather enough data to analyze the patterns so we could adjust the calendar accordingly. Once that was initiated, I was able to explore options for the staffing itself. Part of the solution included bringing on a new team member at part-time. This was a new parent who wanted to balance work and home life, so it was a good solution all around. I’ve noticed from your physician list that your practice includes a variety of people at different stages in their careers. It would be exciting to look at opportunities to adjust the staffing and schedules to meet the different needs on the team, if that was something you wanted me to take on.
Critique. Although this answer is also long, it’s much more compelling, primarily because it’s engaging and conversational in tone. To achieve that effect, the candidate sacrifices detail and process in favor of storytelling. Interspersing comments that relate the information directly back to the current employer is also a good technique.
Want to add some flavor to your job search? Visit Bluebird 1C Tuesday from 7:00 a.m. to 9:00 a.m. to take part in Java, Juice, & Jobs, sponsored by the Neurology Career Center.
This event features networking opportunities with your peers and neurology hiring managers, 40+ employer booths, interactive career-related stations, one-on-one career advice from seasoned AAN members, and giveaways while supplies last.
Enjoy the free breakfast as you start your day at this fun event offering something for everyone— including a visit from Sarah Bellum™. The first 50 attendees will receive gift bags!
For more information, visit AAN.com/AM or the AAN Conferences mobile app and search for Java, Juice, & Jobs.
New treatment targets in Alzheimer’s unlocking new possibilities... We are looking beyond the amyloids.
Learn More
www.cognitotx.com
The AAN is partnering with the Child Neurology Society for today’s Society Spotlight session (formerly Invited Science) from 1:00 p.m. to 3:00 p.m. in Mile High 4CD. Participants will hear updates on the cutting-edge science of hot topics in child neurology from authors giving encore presentations of top research presented at the recent Child Neurology Society meeting.
Presentations and authors include:
1:00 p.m.–1:20 p.m.
Evaluation of the Long-term Effect of Arimoclomol in NPC—48 Months Data from CT-ORZY-NPC-002
Marc C. Patterson, MD, FAAN, FRACP
1:20 p.m.–1:40 p.m.
Infectious Profiling Reveals Potential
Triggers of Pediatric NMDAR Encephalitis: A Large Case-control Study
Alexander Sandweiss, MD, PhD
1:40 p.m.–2:00 p.m.
Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures
Alexandra Raquel Santana Almansa, MD
2:00 p.m.–2:20 p.m.
Gender Representation in Leadership Roles and Awards in the Child Neurology Society
Jaclyn Martindale, DO
2:20 p.m.–2:40 p.m.
Astrocyte-targeted Gene Therapy Demonstrates Safety and Efficacy in Two Murine Models of Vanishing White Matter Disease
Joshua Bonkowsky, MD, PhD
2:40 p.m.–3:00 p.m.
Myelin Plasticity Promotes Thalamocortical Hypersynchrony and Generalized Epilepsy Progression
Juliet Klasing Knowles, MD
Innovative solutions in generalized myasthenia gravis (gMG), backed by a history of excellence in neurology
UCB is excited to introduce our recent advancements for adults living with gMG.
Kamilla, living with MG
Explore the possibilities at booth 1483
©2024 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-DA-2400032
The AAN recognizes the 2024 AAN scientific award recipients and their contributions to the art and science of neurology.
AAN NEURO-INFECTIOUS DISEASE AWARD
Sponsored by the American Academy of Neurology.
Prashanth S. Ramachandran, Jr., MBBS, BMedSci, PhD, FRACP
University of Melbourne, Ashwood, Victoria, Australia
ALLIANCE AWARD: S. WEIR MITCHELL
Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.
Shane Arsenault, MD, MSc, MPH
Memorial University of Newfoundland, Newfoundland and Labrador, Canada
BHUWAN GARG HIGH SCHOOL NEUROSCIENCE RESEARCH PRIZE
Sponsored by the American Academy of Neurology and the Child Neurology Society.
Allison Duh
Burlingame High School, Burlingame, CA
BRUCE S. SCHOENBERG INTERNATIONAL AWARD IN NEUROEPIDEMIOLOGY
Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.
Enrique Gomez Figueroa, MD, MSc
Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico
CAREER DEVELOPMENT AWARD
Funded by the American Academy of Neurology.
Cole Harrington, MD, PhD
Ohio State University, Columbus, OH
Divakar Mithal, MD, PhD
Northwestern University, Lurie Children's Hospital, Chicago, IL
CLINICAL RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology.
Monique Anderson, MD, PhD
Massachusetts General Hospital, Boston, MA
Emanuele Barca, MD, PhD
Columbia University, New York, NY
David Fischer, MD
University of Pennsylvania, Philadelphia, PA
CLINICAL RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology.
John Rhee, MD, MPH
McLean Hospital / Harvard Medical School, Cambridge, MA
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALS
Funded by The ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology.
Jill Goslinga, MD, MPH
University of California, San Francisco, San Francisco, CA
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALS AND RELATED DISORDERS (CREATE)
Funded by the CReATe Consortium and American Brain Foundation in collaboration with the American Academy of Neurology.
Marijne Vandebergh, PhD
University of Antwerp, Antwerpen, Belgium
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN FTD
Funded by The Holloway Family Fund of The Association for Frontotemporal Degeneration and American Brain Foundation in collaboration with the American Academy of Neurology.
Rowan Saloner, PhD
University of California, San Francisco, San Francisco, CA
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN LBD
Funded by the Alzheimer's Association and the American Brain Foundation.
George Kannarkat, MD, PhD
University of Pennsylvania, Philadelphia, PA
CLINICAL RESEARCH
TRAINING SCHOLARSHIP IN MULTIPLE SCLEROSIS
Funded by Bristol-Myers Squibb and the American Brain Foundation in collaboration with the American Academy of Neurology.
Simon Thebault, MD
University of Pennsylvania, Philadelphia, PA
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN NEURODISPARITIES
Funded by the American Brain Foundation in collaboration with the American Academy of Neurology.
Malya Sahu, MD
Johns Hopkins University, Baltimore, MD
Elizabeth Chernyak, MD
Maimonides Medical Center, Brooklyn, NY
CLINICAL RESEARCH
TRAINING SCHOLARSHIP IN PARKINSON'S DISEASE
Funded by the Parkinson's Foundation and American Brain Foundation in collaboration with the American Academy of Neurology.
Brittany Krzyzanowski, PhD
Barrow Neurological Institute, Phoenix, AZ
CLINICAL RESEARCH
TRAINING SCHOLARSHIP IN PERIPHERAL NEUROPATHY
Funded by the Foundation for Peripheral Neuropathy through the American Brain Foundation in collaboration with the American Academy of Neurology.
Francesco Michelassi, MD, PhD
Columbia University, New York, NY
DREIFUSS-PENRY EPILEPSY AWARD
Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Corporation; GlaxoSmithKline, Inc.; Novartis; OrthoMcNeil Pharmaceutical, Inc.; Pfizer Inc; Shire Pharmaceuticals Group; and UCB Pharma.
Erin C. Conrad, MD
University of Pennsylvania, Philadelphia, PA
HAROLD WOLFF-JOHN GRAHAM AWARD: AN AWARD FOR HEADACHE/
FACIAL PAIN RESEARCH
Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.
Chia-Chun Chiang, MD
Mayo Clinic, Rochester, MN
Yohance Mandela Allette, MD, PhD
Penn State Health Hershey Medical Center, Hershey, PA
Raima M. Amin, MD
Franciscan Neurology Associates, Seattle, WA
Yvette Michelle Brown-Shirley, MD
Barrow Neurological Institute, Phoenix, AZ
Angela Lu, MD, FAAN
WVU Neurology, Uniontown, PA
Jose Antonio Montes-Rivera, MD
UConn Health, Farmington, CT
Sameh Morkous, MD, FAAN
Lehigh Valley Pediatric Neurology Allentown, PA
Aaron Lane Nelson, MD, FAAN
NYU Langone Health, New York, NY
Meghna Rajaprakash, MD
Kennedy Krieger Institute, Baltimore, MD
Talita D'Aguiar Rosa, MD
Duke University, Durham, NC
Timothy J. Young, MD
Mayo Clinic Health System, Eau Claire, WI
Sponsored by the American Academy of Neurology.
Galit L. Dunietz, MA, MPH, PhD
University of Michigan, Ann Arbor, MI
Mathula Thangarajh, MD, PhD, FAAN
Virginia Commonwealth University, Glen Allen, VA
Raina Croff, PhD
Oregon Health & Science University, Portland, OR
Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.
Steven Vernino, MD, PhD, FAAN
UT Southwestern Medical Center, Dallas, TX
Sponsored by the American Academy of Neurology and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.
Rhonda Voskuhl, MD
UCLA, Los Angeles, CA
Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.
Abby L. Olsen, MD, PhD
University of Pittsburgh, Philadelphia, PA
Sponsored by the American Academy of Neurology.
Alison L. Christy, MD, PhD
Providence Health & Services, Pediatric Specialty Clinic, Portland, OR
M. BRASS STROKE RESEARCH AWARD
Funded by the American Heart Association and American Brain Foundation in collaboration with the American Academy of Neurology.
Ana-Lucia Garcia Guarniz, MD
Massachusetts General Hospital, Boston, MA
CLINICAL TRANSLATIONAL RESEARCH
Funded by the McKnight Brain Research Foundation through the American Brain Foundation, and the American Academy of Neurology.
Haopei Yang, PhD
Stanford University, Stanford, CA
MEDICAL STUDENT ESSAY
AWARD: ROLAND P. MACKAY
Sponsored by the American Academy of Neurology.
Allison Brown, MS
Hackensack Meridian School of Medicine, Bloomfield, NJ
MEDICAL STUDENT ESSAY
AWARD: SAUL R. KOREY
Sponsored by the American Academy of Neurology.
Gabriella Miggins
McGovern Medical School at UTHealth, Houston, TX
MEDICAL STUDENT ESSAY
AWARD: LEWIS P. ROWLAND
Sponsored by the American Academy of Neurology.
Mimi Lam, BS
University of California, Riverside School of Medicine, Riverside, CA
MEDICAL STUDENT ESSAY
AWARD: G. MILTON SHY
Sponsored by the American Academy of Neurology.
Richard I. Suarez, JM
Florida International University Herbert Wertheim College of Medicine, Miami, FL
MICHAEL S. PESSIN STROKE LEADERSHIP PRIZE
Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues.
Antreas Charidimou, MD, PhD, MSc Boston University Chobanian & Avedisian School of Medicine, Boston, MA
MITCHELL B. MAX AWARD FOR NEUROPATHIC PAIN
Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max.
Daniela Salvemini, PhD
Saint Louis University, St. Louis, MO
MOVEMENT DISORDERS RESEARCH AWARD
Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation.
David Rubinsztein, MBChB, BSc (Med) Hons, PhD
University of Cambridge, Cambridge, United Kingdom
NEUROSCIENCE RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology.
Hashmat Ghanizada, MD, PhD
University of Copenhagen, Copenhagen, Denmark
Alexander Gill, MD, PhD
Johns Hopkins University, Baltimore, MD
Ho Namkung, PhD
California Institute of Technology, Pasadena, CA
Continued on page 24
Celebrate These 2024 AAN Scientific Award Recipients continued from page 23
NEURO-ONCOLOGY INVESTIGATOR AWARD
Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.
Yazmin Odia, MD, FAAN, MS
Miami Cancer Institute, Miami, FL
NEURO-ONCOLOGY SCIENTIFIC AWARD
Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.
William Weiss, MD, PhD
University of California, San Francisco, San Francisco, CA
NEUROSCIENCE RESEARCH PRIZE
Sponsored by the American Academy of Neurology.
Sreekar Baddepudi
Evergreen Valley High School, San Jose, CA
Thrisha Kalpatthi
North Allegheny Senior High School, Mars, PA
Syed Zaidi
Ossining High School, Ossining, NY
NORMAN GESCHWIND PRIZE IN BEHAVIORAL NEUROLOGY
Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.
David Irwin, MD
University of Pennsylvania, Philadelphia, PA
PRACTICE RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology
Andrew Huang, MD
University of Rochester, Rochester, NY
POTAMKIN PRIZE FOR RESEARCH IN PICK'S, ALZHEIMER'S, AND RELATED DISEASES
Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family.
Francisco T. Lopera, MD, PhD
Universidad de Antioquia, Medellin, Colombia
RICHARD OLNEY CLINICIAN SCIENTIST DEVELOPMENT AWARD IN ALS
Funded by The ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology.
Eleanor Thomas, MD, PhD Emory University, Atlanta, GA
ROBERT KATZMAN, MD CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALZHEIMER'S AND DEMENTIA RESEARCH
Funded by the Alzheimer's Association through the American Brain Foundation in collaboration with the American Academy of Neurology.
Andrew Breithaupt, MD
University of California, San Francisco, San Francisco, CA
SHEILA ESSEY AWARD: AN AWARD FOR ALS RESEARCH
Presented by the AAN and the ALS Association and supported through the philanthropy of the Essey family, the American Brain Foundation and the ALS Association.
Eva L. Feldman, MD, PhD, FAAN University of Michigan / Michigan Medicine, Ann Arbor, MI
SLEEP SCIENCE AWARD
Sponsored by the American Academy of Neurology and the Sleep Section and endowed by Cephalon, Inc.
Brendan P. Lucey, MD, Msci
Washington University School of Medicine, St. Louis, MO
SUSAN S. SPENCER, MD, CLINICAL RESEARCH TRAINING SCHOLARSHIP IN EPILEPSY
Funded by the American Epilepsy Society, Epilepsy Foundation, and American Brain Foundation in collaboration with the American Academy of Neurology.
Jillian McKee, MD, PhD
Children’s Hospital of Philadelphia, Philadephia, PA
WAYNE A. HENING SLEEP MEDICINE INVESTIGATOR AWARD
Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.
Stuart McCarter, MD
Mayo Clinic, Rochester, MN
Embark on a journey of creativity, fun, and a well-deserved escape from the hustle and bustle of the conference at one of the Brain Breaks stations located throughout the convention center!
These delightful opportunities for pause in your day’s learning adventure will leave you refreshed for your next session. Embrace your inner child as you create your own unique sculpture from modeling clay or stop and reflect on your time at the meeting to send a note back home to loved ones. Or, if you’re simply looking for a quiet retreat, then head to the Bluebird level for designated low-key space to relax, read, take personal calls, or work on… whatever. Private meeting pods are also available in Lobby D on a first-come, first-served basis. Brain Breaks and quiet time are not just a pause—they’re an essential part of your conference experience. Embrace the opportunity to recharge, connect, and return to the sessions with a refreshed and invigorated mind!
Kiran Patil MD FAAN @KiranPatilMD
Great listening to @drsanjaygupta
“If you are not talking Somebody will” “Sick care system vs Health care system“ “Stories of humanity to impact people outside of field of brain health“
@AANmember #AANAM @nsanar @CarlayneJackson #brainhealth
Carter Butson
Awesome talk from @drsanjaygupta at #AANAM Neurology Conference! 3 key takeaways:
1. Share stories about your patients to make a broader point
2. Don’t shy away from talking about uncertainty with your patients
3. It’s hard to hate close up
Dr. Casey F. Jeffreys @CaseyJeffreysMD
I’m going to make the argument that carrying my backpack of pumping stuff basically counts as rucking…right? Grateful to @AANmember for considering nursing/pumping parents at #AANAM
Olivia Begasse de Dhaem @obegassededhaem
Such a pleasure and honor spending time with the brilliant and wise Dr @headacheMD #AANAM
Avi Singh Gandh, MD Atlanta, Georgia
1
What brings you to the Annual Meeting?
I’m a neurology resident at Emory. Neurology was something that always spoke to my heart. This is as big as it gets—just to see the different dimensions neurologists have ventured into, connecting in directions my soul speaks to. Especially, I’m huge on medical education, so meeting a lot of program directors and hearing their takes on graduate medical education. The other thing I do is something called medical poetry. That’s something I’m endorsing as well, just to bring art to neurology and medicine in general.
So it’s good to share what out-of-the-box ideas we have. It doesn’t get any grander than AAN. And this is my first time here, so I’m loving it.
Raul Augusto Comme Debroth, MD
Santo Domingo, Dominican Republic
What brought you to the Annual Meeting?
1
One of my fellow students who was coming here, he said he prefers the American Academy of Neurology’s Annual Meeting over the one I have been going to. So I’ll see! But the other reason I wanted to come is to see if I could meet some of my old fellows.
Mohamed Ibrahim Aleem, MD, FAAN Trichy, India
What brings you to the Annual Meeting?
Because it's a very important meeting. We’re learning a lot through the American Academy of Neurology— they’re helping the whole universe. I’m the vice chair of the AAN Ethics Section. I was also selected for the Volunteer Service Award, so I will receive that award here.
Munire Kilinc Toprak, MD, PhD Ankara. Türkiye
What would you tell someone who’s thinking about going to the Annual Meeting?
I would recommend it for the updated knowledge in medicine. That’s something wonderful. And we can meet people face-to-face who we usually only see in the Neurology® journal. These are nice things if you have 30 years of background in neurology.
Kristina Ellis, PA Anchorage, Alaska
What are you looking forward to at this Annual Meeting?
There’s a lot that I’m looking forward to seeing in person here, like spine-related education—that’s super interesting to me because I cross both neurosurgery and neurology. And then when I get home, I’m going to use AAN Rewind to do the full headache track, because I see headache neurology patients in clinic.
You spoke, we listened: Continuum® Audio is now available on your favorite podcast platform—no special app or log-in needed!
Listen now wherever you get your podcasts.
Through groundbreaking research, expansive partnerships, and dedication to ensuring equitable access to care, Genentech is committed to creating a tomorrow in which neurological disorders no longer limit human potential.
Luke Xie Researcher Neuroscience, Genentech
neuron